These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19484457)

  • 1. Treating refractory scleritis with infliximab.
    Ahn SJ; Oh JY; Kim MK; Wee WR
    Jpn J Ophthalmol; 2009 May; 53(3):286-7. PubMed ID: 19484457
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive therapy.
    Weiss K; Rieger R; Keitzer R; Pleyer U
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1735-7. PubMed ID: 17674021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for the treatment of refractory scleritis.
    Doctor P; Sultan A; Syed S; Christen W; Bhat P; Foster CS
    Br J Ophthalmol; 2010 May; 94(5):579-83. PubMed ID: 19955205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in a patient with refractory necrotizing scleritis associated with relapsing polychondritis.
    Jabbarvand M; Fard MA
    Ocul Immunol Inflamm; 2010 Jun; 18(3):216-7. PubMed ID: 20482401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab therapy for the treatment of refractory ocular inflammatory disease.
    Sobrin L; Kim EC; Christen W; Papadaki T; Letko E; Foster CS
    Arch Ophthalmol; 2007 Jul; 125(7):895-900. PubMed ID: 17620567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment.
    Kontkanen M; Paimela L; Kaarniranta K
    Acta Ophthalmol; 2010 May; 88(3):e96-7. PubMed ID: 19758399
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of refractory anterior diffuse scleritis with infliximab].
    Díaz-Valle D; Miguélez Sánchez R; Fernández Espartero MC; Pascual Allen D
    Arch Soc Esp Oftalmol; 2004 Aug; 79(8):405-8. PubMed ID: 15306969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for the treatment of active scleritis.
    Sen HN; Sangave A; Hammel K; Levy-Clarke G; Nussenblatt RB
    Can J Ophthalmol; 2009 Jun; 44(3):e9-e12. PubMed ID: 19506593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors.
    Ragam A; Kolomeyer AM; Fang C; Xu Y; Chu DS
    Ocul Immunol Inflamm; 2014 Dec; 22(6):469-77. PubMed ID: 24354512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for progressive peripheral ulcerative keratitis in a patient with juvenile rheumatoid arthritis.
    Oh JY; Kim MK; Wee WR
    Jpn J Ophthalmol; 2011 Jan; 55(1):70-1. PubMed ID: 21331698
    [No Abstract]   [Full Text] [Related]  

  • 12. [Infliximab in the treatment of necrotizing scleritis associated to seropositive rheumatoid arthritis].
    Abalos Medina GM; Gónzalez Domínguez J; Ruiz Villaverde G; Raya Alvarez E
    Med Clin (Barc); 2010 Feb; 134(5):235-6. PubMed ID: 19359007
    [No Abstract]   [Full Text] [Related]  

  • 13. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents in the management of inflammatory eye diseases.
    Michalova K; Lim L
    Curr Allergy Asthma Rep; 2008 Jul; 8(4):339-47. PubMed ID: 18606088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapy for refractory scleritis: a new treatment perspective.
    de Fidelix TS; Vieira LA; de Freitas D; Trevisani VF
    Int Ophthalmol; 2015 Dec; 35(6):903-12. PubMed ID: 26319144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posterior scleritis in Cogan's syndrome.
    Gonçalves RM; Curi AL; Campos WR; Oréfice F; Machado DO
    Ocul Immunol Inflamm; 2004 Jun; 12(2):149-52. PubMed ID: 15512985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
    Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis.
    Cazabon S; Over K; Butcher J
    Eye (Lond); 2005 Feb; 19(2):222-4. PubMed ID: 15258602
    [No Abstract]   [Full Text] [Related]  

  • 20. Regression of vasoproliferative tumor with systemic infliximab.
    Japiassú RM; Brasil OF; Cunha AL; de Souza EC
    Ophthalmic Surg Lasers Imaging; 2008; 39(4):348-9. PubMed ID: 18717448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.